

**Reference:** FOI 35755 GLO 11M

**Subject:** Community Dermatology Services

*I can confirm that the CCG does hold the information requested; please see responses below:*

QUESTION	RESPONSE
<p>1. <b>Is your Community Dermatology Service provided as a separate contract or is it integrated into the secondary care service?</b></p>	<p>The CCG does not commission a community dermatology service. Dermatology services are provided by our local acute hospital – <a href="#">Gloucestershire Hospitals NHS Foundation Trust</a></p>
<p>2. <b>Who is the current provider of the Community Dermatology service?</b></p>	<p>Not applicable</p>
<p>3. <b>Is the contract delivered in partnership with other providers? If so, who are the providers and from what sector (e.g. third sector, contractors)</b></p>	
<p>4. <b>What is the contract length and contract value of the current Community Dermatology contract?</b></p>	
<p>5. <b>Does the current service utilise Artificial Intelligence?</b></p>	
<ul style="list-style-type: none"> <li><b>If yes, which parts of the pathway is the AI used in? What are the success rates for AI compared to consultants in the service?</b></li> </ul>	
<ul style="list-style-type: none"> <li><b>If No, Would the CCG consider commissioning AI as part of a future service?</b></li> </ul>	

<p><b>6. Would it be possible to get a copy of the current service specification?</b></p>	<p>Not applicable</p>
<p><b>7. When is the current Community Dermatology service due to be re-tendered?</b></p>	
<p><b>8. Is this date before contract extension (if so what is the extension period and likelihood of extension)?</b></p>	
<p><b>9. Is it anticipated the re-tendered service will adhere to the same model and specification as the current Community Dermatology service?</b></p>	
<p><b>a. If not, how do you expect this service to differ? Will you be undertaking market engagement ahead of any procurement process to inform this model?</b></p>	
<p><b>b. If yes, do you anticipate the contract length and financial envelope to remain the same or efficiency savings to be applied? What percentage reduction would this be?</b></p>	
<p><b>10. Has the current Community Dermatology service met all of the contracted KPIs during the lifetime of the contract?</b></p>	
<p><b>11. Has the current provider of the Community Dermatology Service been served with any performance notices? If yes, when were they served and what for?</b></p>	
<p><b>12. Are there any areas of particular concern within the CCGs population which the Community Dermatology service could be addressing more effectively?</b></p>	

<b>13. Are there any areas of exceptional practice and/or innovation in the current Community Dermatology Service which stand out to the CCG?</b>	Not applicable
<b>14. What is the current Patient Satisfaction Rate for the Community Dermatology Service? Has this remained consistent or has there been fluctuations (reduced or improved)?</b>	
<b>15. Which virtual/remote platforms are used in the current Community Dermatology Service?</b> <ul style="list-style-type: none"> <li>• Telephone</li> <li>• Video General, e.g. WhatsApp, Skype, Zoom</li> <li>• Video Bespoke, e.g. Q-Doc, Attend Anywhere</li> </ul>	
<b>16. Has the Community Dermatology Service continued to operate routine appointments during the Covid-19 pandemic via remote methods alongside Emergency/Urgent referrals?</b>	

*The information provided in this response is accurate as of 26 June 2020 and has been authorised for release by Mark Walkingshaw, Deputy Accountable Officer/Director of Commissioning for NHS Gloucestershire CCG.*